cannabidiol and Back-Pain

cannabidiol has been researched along with Back-Pain* in 2 studies

Other Studies

2 other study(ies) available for cannabidiol and Back-Pain

ArticleYear
Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
    Pain medicine (Malden, Mass.), 2022, 04-08, Volume: 23, Issue:4

    To compare the effectiveness, safety, and tolerability of add-on nabiximols (NBX) oromucosal spray vs typical oral long-acting opioid (LAO) analgesics in patients with severe (± chronic) peripheral neuropathic back pain poorly responsive to other treatments.. Retrospective analysis of anonymized, propensity score-matched data from the German Pain e-Registry of adult outpatients who initiated NBX or LAO between March 2017 and March 2020.. Data were analyzed from propensity score-matched patients treated with NBX (n = 655) or LAO (n = 655): mean age ≈51 years; 57% female; mean pain duration ≈2.6 years; chronic pain 61%; severe dysfunctional pain 93%. At 6 months, NBX was noninferior to LAO for overall symptom relief, based on the least-squares mean difference between cohorts in change from baseline in patient-reported, pain-related aggregated nine-item scale scores (-27.84%; 95% confidence interval [CI] -29.71 to -25.96; P < 0.001) and individual pain-related scale scores. Subsequent prespecified superiority analysis of the primary endpoint showed that NBX was superior to LAO: all secondary endpoints measuring symptoms of pain and physical function improved significantly with NBX and LAO, with between-group differences favoring NBX (all P < 0.001). Fewer patients treated with NBX than LAO experienced treatment-related adverse events (25.5% vs 76.0%; P < 0.001) or discontinued treatment because of treatment-related adverse events (7.9% vs 29.3%; P < 0.001).. Within study limitations (e.g., observational design, all potential biases), add-on NBX was superior to and better tolerated than add-on treatment with typical oral LAO analgesics in patients with neuropathic back pain inadequately controlled by recommended/established systemic therapies.

    Topics: Adult; Analgesics; Analgesics, Opioid; Back Pain; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Neuralgia; Registries; Retrospective Studies

2022
Lack of efficacy of cannabidiol for relieving back pain: time to re-set expectations?
    The Medical journal of Australia, 2021, Volume: 214, Issue:8

    Topics: Back Pain; Cannabidiol; Emergency Service, Hospital; Humans; Low Back Pain; Motivation

2021